Evidence map›Paper›PMID 31787751›Full record

ArticleBritish journal of cancer2020

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.

Max M Wattenberg, Daniella Asch, Shun Yu, Peter J O'Dwyer, Susan M Domchek, Katherine L Nathanson, Mark A Rosen, Gregory L Beatty, Evan S Siegelman, Kim A Reiss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Pooled it
  5. Pooled it
  6. Trial
  7. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Max M WattenbergDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniella AschDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shun YuDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Peter J O'DwyerDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Susan M DomchekDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Katherine L NathansonDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mark A RosenDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gregory L BeattyDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Evan S SiegelmanDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kim A ReissDivision of Hematology-Oncology, Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kimreiss@pennmedicine.upenn.edu.

Funding

HEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1M
CANCER CLINICAL EPIDEMIOLOGY TRAINING GRANTT32CA009679 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Richard Aplenc, Karen Glanz · 1992 to 2026
$11.1M
NCI NIH HHS T32 CA009679NHLBI NIH HHS T32 HL007439
6 · The paper itself

Abstract

backgroundRetrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC). However, the objective response rate (ORR) and real-world progression free survival (rwPFS) achieved with such treatment remain ill-defined.

methodsTwenty-six patients with advanced-stage mut-positive PDAC who had been treated with platinum-based therapy were matched by age, race and sex to 52 platinum-treated control PDAC patients. Responses to therapy were determined by RECIST v1.1, performed by blinded radiology review. Measured outcomes included ORR and rwPFS.

resultsThe ORR in mut-positive patients was 58% compared to 21% in the control group (p = 0.0022). There was no significant difference in ORR between platinum regimens in mut-positive patients (p = 0.814), whereas in control patients, the only observed responses were to FOLFIRINOX. rwPFS was 10.1 mo. for mut-positive patients and 6.9 mo. for controls (HR 0.43; 95% CI 0.25-0.74; 0.0068).

conclusionMut-positive PDAC has a high ORR and prolonged rwPFS to platinum-based chemotherapy. These findings may have implications particularly in the neoadjuvant setting, and for future clinical trial design, and highlight the importance of early germline testing in patients with PDAC.

Indexed as

AdultAgedAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinCarcinoma, Pancreatic DuctalCase-Control StudiesCisplatinDeoxycytidineFanconi Anemia Complementation Group N ProteinFemaleFluorouracilGemcitabineGerm-Line Mutation130-nm albumin-bound paclitaxelAlbuminsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCisplatinDeoxycytidineFanconi Anemia Complementation Group N ProteinFluorouracilfolfirinoxGemcitabineIrinotecanLeucovorinOrganoplatinum CompoundsOxaliplatinPaclitaxelPALB2 protein, human

Identifiers

PMID31787751
PMCPMC7000723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.